We have seen a steady increase in the use of blood based biomarkers, the conversion rates from diagnosis ... ejection fraction indication for Tirzepatide. We believe the positive Phase 3 data ...

Plus bear in mind that Canada is the second largest semaglutide market in the world ... 2030s and then U.S. a little bit later and then tirzepatide more into sort of the mid-2030s.

From ‘Ozempic face’ to ‘Ozempic fingers’ and even ‘Wegovy butt,’ the potential side effects of weight loss medications have ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!